<DOC>
	<DOCNO>NCT00140647</DOCNO>
	<brief_summary>The purpose study determine ramipril and/or rosiglitazone retard progression atherosclerosis evaluate serial carotid intermedial thickness measurement .</brief_summary>
	<brief_title>The Study Atherosclerosis With Ramipril Rosiglitazone</brief_title>
	<detailed_description>STARR multi-centre , international , randomize control clinical trial 2x2 factorial design , evaluate effect ramipril rosiglitazone atherosclerosis progression , determine B-mode carotid ultrasound ( US ) . It design substudy DREAM ( Diabetes Reduction Assessment ramipril rosiglitazone Medications ) Trial . The study design enroll 1,200 study participant follow propose average 3.75 year . SIGNIFICANCE OF THE PROPOSED RESEARCH : With regard ramipril study provide important mechanistic data regard potential benefit ACE inhibitor therapy atherosclerosis inference reduce CV risk low risk young population study previous trial . In population clinical outcome trial focus primarily CV event would difficult conduct due expect fairly low event rate . If study atherosclerosis positive , may provide rational therapy subset patient without overt CVD diabetes , impair glucose tolerance impair fast glucose .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>impaired glucose tolerance ( FPG &lt; 7 mmol/L 126 mg/dL &amp; 2hr PG 7.811.0 mmol/l [ 140199 mg/dl ] 75 g OGTT impair glucose tolerance ( FPGâ‰¥ 6.1 mmol/l [ 110 mg/dl ] ) diabetes ( i.e . FPG &lt; 7.0 mmol/l [ 126 mg/dl ] ) technically adequate baseline carotid ultrasound examination current use ACEinhibitor ( ACEI ) thiazolidinedione ( TZD ) know hypersensitivity ACEI prior use antidiabetic medication 9with exception pregnancy ) use systemic glucocorticoid niacin congestive heart failure EF &lt; 40 % exist cardiovascular disease ( previous MI , stroke , angina , uncontrolled hypertension ) diabetes renal hepatic disease major illness use another experimental drug pregnant unwilling use reliable contraception major psychiatric disorder disease affect glucose tolerance unwillingness randomize sign inform consent know uncontrolled substance abuse inability communicate research staff</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>carotid artery</keyword>
	<keyword>ramipril</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>impaired fasting glucose</keyword>
	<keyword>diabetes prevention</keyword>
</DOC>